228 related articles for article (PubMed ID: 17075122)
61. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
[TBL] [Abstract][Full Text] [Related]
62. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
Jänne PA; von Pawel J; Cohen RB; Crino L; Butts CA; Olson SS; Eiseman IA; Chiappori AA; Yeap BY; Lenehan PF; Dasse K; Sheeran M; Bonomi PD
J Clin Oncol; 2007 Sep; 25(25):3936-44. PubMed ID: 17761977
[TBL] [Abstract][Full Text] [Related]
63. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Aulino J; Muldowney NJ; Hatakeyama H; Baumann J; Burkey B; Netterville J; Sinard R; Yarbrough WG; Cmelak AJ; Slebos RJ; Shyr Y; Parker J; Gilbert J; Murphy BA
Ann Oncol; 2010 Apr; 21(4):864-870. PubMed ID: 19850643
[TBL] [Abstract][Full Text] [Related]
64. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL; Pellegrini C; Merla E; Ballerini F; Fabbri A; Guarini A; Pavone V; Quintini G; Puccini B; Vigliotti ML; Stefoni V; Derenzini E; Broccoli A; Gandolfi L; Quirini F; Casadei B; Argnani L; Baccarani M
Hematol Oncol; 2013 Dec; 31(4):179-82. PubMed ID: 23108928
[TBL] [Abstract][Full Text] [Related]
65. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Schneider BJ; Kalemkerian GP; Kraut MJ; Wozniak AJ; Worden FP; Smith DW; Chen W; Gadgeel SM
J Thorac Oncol; 2008 Dec; 3(12):1454-9. PubMed ID: 19057272
[TBL] [Abstract][Full Text] [Related]
66. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Quoix E; Lebeau B; Depierre A; Ducolone A; Moro-Sibilot D; Milleron B; Breton JL; Lemarie E; Pujol JL; Brechot JM; Zalcman G; Debieuvre D; Vaylet F; Vergnenegre A; Clouet P
Ann Oncol; 2004 Jan; 15(1):38-44. PubMed ID: 14679117
[TBL] [Abstract][Full Text] [Related]
67. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
Petrylak DP; Tagawa ST; Kohli M; Eisen A; Canil C; Sridhar SS; Spira A; Yu EY; Burke JM; Shaffer D; Pan CX; Kim JJ; Aragon-Ching JB; Quinn DI; Vogelzang NJ; Tang S; Zhang H; Cavanaugh CT; Gao L; Kauh JS; Walgren RA; Chi KN
J Clin Oncol; 2016 May; 34(13):1500-9. PubMed ID: 26926681
[TBL] [Abstract][Full Text] [Related]
68. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Price N; Dreicer R
Clin Prostate Cancer; 2004 Dec; 3(3):141-3. PubMed ID: 15636679
[No Abstract] [Full Text] [Related]
69. Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Piperdi B; Ling YH; Perez-Soler R
J Thorac Oncol; 2007 Aug; 2(8):715-21. PubMed ID: 17762337
[TBL] [Abstract][Full Text] [Related]
70. Activity of bortezomib in advanced non-small-cell lung cancer.
Reddy KG
Clin Lung Cancer; 2004 Nov; 6(3):141-2. PubMed ID: 15555213
[No Abstract] [Full Text] [Related]
71. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
[TBL] [Abstract][Full Text] [Related]
72. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Edelman MJ
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
Natale R; Blackhall F; Kowalski D; Ramlau R; Bepler G; Grossi F; Lerchenmüller C; Pinder-Schenck M; Mezger J; Danson S; Gadgeel SM; Summers Y; Callies S; André V; Das M; Lahn M; Talbot D
J Thorac Oncol; 2014 Nov; 9(11):1704-8. PubMed ID: 25436803
[TBL] [Abstract][Full Text] [Related]
74. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Chiappori A; Williams C; Northfelt DW; Adams JW; Malik S; Edelman MJ; Rosen P; Van Echo DA; Berger MS; Haura EB
J Thorac Oncol; 2014 Jan; 9(1):121-5. PubMed ID: 24346101
[TBL] [Abstract][Full Text] [Related]
75. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
[TBL] [Abstract][Full Text] [Related]
76. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Di Bella N; Taetle R; Kolibaba K; Boyd T; Raju R; Barrera D; Cochran EW; Dien PY; Lyons R; Schlegel PJ; Vukelja SJ; Boston J; Boehm KA; Wang Y; Asmar L
Blood; 2010 Jan; 115(3):475-80. PubMed ID: 19965689
[TBL] [Abstract][Full Text] [Related]
77. A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.
Atagi S; Daimon T; Okishio K; Komuta K; Okano Y; Minato K; Kim YH; Usui R; Tabata C; Tamura A; Kawahara M
Thorac Cancer; 2023 Oct; 14(29):2941-2949. PubMed ID: 37609677
[TBL] [Abstract][Full Text] [Related]
78. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Rosenberg JE; Halabi S; Sanford BL; Himelstein AL; Atkins JN; Hohl RJ; Millard F; Bajorin DF; Small EJ;
Ann Oncol; 2008 May; 19(5):946-50. PubMed ID: 18272914
[TBL] [Abstract][Full Text] [Related]
79. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
80. Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
Pillai RN; Fennell DA; Kovcin V; Ciuleanu TE; Ramlau R; Kowalski D; Schenker M; Yalcin I; Teofilovici F; Vukovic VM; Ramalingam SS
J Clin Oncol; 2020 Feb; 38(6):613-622. PubMed ID: 31829907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
